

T +91 22 6606 1000
F +91 22 6606 1200
E legal.info@ajantapharma.com
W www.ajantapharma.com



8<sup>th</sup> May 2024

BSE LIMITED	National Stock Exchange of India,
Phiroze Jeejeebhoy Towers	Exchange Plaza, 5 <sup>th</sup> Floor, Plot no.
Dalal Street,	C/1, G Block, Bandra Kurla Complex,
Mumbai – 400001	Bandra (East), Mumbai – 400 051
Scrip Code: BSE – AJANTPHARM 532331	Scrip Code: NSE AJANTPHARM EQ
Scrip Coue. DSE – AJAIVII HARM 552551	Scrip Coue. INSE AJAINTI HARM EQ

## Sub: Written transcript of Earnings call conducted on 2<sup>nd</sup> May 2024

Dear Sir / Madam,

Further to our communication dated 2<sup>nd</sup> May 2024 on earnings call, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, written transcript of the earnings call held on 2<sup>nd</sup> May 2024 at 4.30 p.m. has been uploaded on the Company's website and can be accessed through the link https://ajantapharma.com//images/Earnings-Call-Transcript-Q4-(Jan-Mar)-2023-24.pdf

This is for your information and records please.

Yours faithfully,

## GAURANG SHAH

*VP* – *Legal & Company Secretary*